Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer {u2014} An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information